Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma - Wikidata - wikimedia - TriplyDB

Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma

Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma

http://www.wikidata.org/entity/Q33673131

about

Volume doubling time of lung adenocarcinomas considering epidermal growth factor receptor mutation status of exon 19 and 21: three-dimensional volumetric evaluation.

P2860

Q47110408-47398CA9-556D-4E79-818A-2453471CC463

P2860

Radiological and Clinical Features associated with Epidermal Growth Factor Receptor Mutation Status of Exon 19 and 21 in Lung Adenocarcinoma

http://www.wikidata.org/entity/Q33673131

description

2017 nî lūn-bûn

@nan

2017 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մարտին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Radiological and Clinical Feat ...... and 21 in Lung Adenocarcinoma

@ast

Radiological and Clinical Feat ...... and 21 in Lung Adenocarcinoma

@en

type

label

Radiological and Clinical Feat ...... and 21 in Lung Adenocarcinoma

@ast

Radiological and Clinical Feat ...... and 21 in Lung Adenocarcinoma

@en

prefLabel

Radiological and Clinical Feat ...... and 21 in Lung Adenocarcinoma

@ast

Radiological and Clinical Feat ...... and 21 in Lung Adenocarcinoma

@en

P1433

Q33673131-E602ACDC-2283-4122-A10B-41C0699B5F9A

P1476

Q33673131-61EAC34F-647F-4B9A-839F-E88FF9D16A13

P2093

Q33673131-07E7A816-43F4-4F4B-865C-77B5A9329E1E

Q33673131-2E0C8C6C-0D98-4C45-BEA1-420FD7006AD6

Q33673131-64304313-662A-4856-8A18-A5A2043C4853

Q33673131-71AC0A31-15F0-4890-BA54-CCB6D5B0E357

Q33673131-78926763-165C-4BC9-AFFA-9B26196E75D0

Q33673131-A5D7855A-0C15-4BDC-B7D8-50989461F5ED

Q33673131-AF0F01F5-E9EA-441D-8CF1-DBF651D45A0F

Q33673131-BCA44F91-397A-494C-BC81-0EA62BB09991

Q33673131-D3843A87-F801-4173-8295-F6DB02D938B4

Q33673131-F81D7CA0-E1AE-4F84-9963-11A1DBAEBD44

P2860

Q33673131-0AF09BAD-C20B-4792-8FAB-9DDDE5BEE1BF

Q33673131-304C48A6-3590-407C-BC1A-F9A270C6FCB9

Q33673131-33EDC56B-8D5C-405B-86A5-7F3E8AE462EE

Q33673131-40FCD7FD-9DE9-4628-8C64-E39184A22E7A

Q33673131-42140222-1922-44E0-914C-62CBA6DB1215

Q33673131-4D77EFFE-B1E9-4DCE-AB3C-A1831BFFAFF3

Q33673131-5B6E0E9B-18D9-4C52-A006-9096949C8A4B

Q33673131-615BEA93-0697-4D1B-BBE4-62348D34EAF3

Q33673131-61946E38-0F27-4E4F-ABF3-5EE211DA1540

Q33673131-649C621C-0A9A-4E20-8313-F897937DE312

P2888

Q33673131-0F1FCBB4-5BDA-43BE-879C-507D13275A93

P304

Q33673131-201A7648-D76A-4F36-B2CB-077DCC3110D6

P31

Q33673131-7AB7E6A5-44C8-4891-A923-45AB556EDA90

P356

Q33673131-1823C8CF-85F5-44A6-BCF8-B6CA9909B878

P407

Q33673131-6C7E3E1D-D71A-49B4-BF30-860F595E9108

P433

Q33673131-30189CAB-DCFC-4B41-B628-47B0722CE5CE

P478

Q33673131-A08B4E67-0390-43AF-95E5-6CBAE6BCCED3

P577

Q33673131-B2908E4E-632E-459F-82D8-FBE02DC8BEDA

P6179

Q33673131-F08108F2-E9AD-4579-88C6-8C475B47A78B

P698

Q33673131-6334B4D3-3184-4FD2-9DF3-22EB437CF2E8

P932

Q33673131-60B6DB48-8292-4E43-96D3-097BD736664C

P356

S41598-017-00511-2

P1433

Scientific Reports

P1476

Radiological and Clinical Feat ...... and 21 in Lung Adenocarcinoma

@en

P2093

Changen Song

http://www.w3.org/2001/XMLSchema#string

Jianping Lu

http://www.w3.org/2001/XMLSchema#string

Qi Liu

http://www.w3.org/2001/XMLSchema#string

Qianwen Zhang

http://www.w3.org/2001/XMLSchema#string

Ruifeng Shi

http://www.w3.org/2001/XMLSchema#string

Runhong Yang

http://www.w3.org/2001/XMLSchema#string

Tao Jiang

http://www.w3.org/2001/XMLSchema#string

Xinrui Wang

http://www.w3.org/2001/XMLSchema#string

Xuan Zheng

http://www.w3.org/2001/XMLSchema#string

Yongwei Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS)

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Epidermal growth factor receptor mutations in lung cancer

Screening for epidermal growth factor receptor mutations in lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)

Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.

P2888

s41598-017-00511-2

P304

364

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-00511-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084130642

http://www.w3.org/2001/XMLSchema#string

P698

28336963

http://www.w3.org/2001/XMLSchema#string

P932

5428650

http://www.w3.org/2001/XMLSchema#string